← All trials
NCT03474276
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2018
- Primary completion
- Mar 30, 2019
- Completion date
- Mar 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 1320
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Institut PasteurLead sponsor
- Institut PasteurCollaborator
- Institut PasteurOverall official - principal investigator
- Action Contre la FaimCollaborator
- Centre de Recherches Médicales et Sanitaires, NigerCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.